Norman J. Lacayo

Hematology | Oncology

725 Welch Rd
Palo Alto, CA 94304

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Real-world experience with IDH inhibitors in pediatric patients with IDH1- and IDH2-mutated acute myeloid leukemia and myelodysplastic syndrome.

Real-world experience with IDH inhibitors in pediatric patients with IDH1- and IDH2-mutated acute myeloid leukemia and myelodysplastic syndrome.

Journal: Haematologica

Published: May 12, 2026

Venetoclax in combination with cytarabine with or without idarubicin or azacitidine in children, adolescents, and young adults with relapsed or refractory acute myeloid leukaemia (VENAML): a multicentre, phase 1 expansion study.

Venetoclax in combination with cytarabine with or without idarubicin or azacitidine in children, adolescents, and young adults with relapsed or refractory acute myeloid leukaemia (VENAML): a multicentre, phase 1 expansion study.

Journal: The Lancet. Haematology

Published: January 21, 2026

Tumor-induced dendritic cell deregulation perturbs T cell proliferation and predicts clinical outcome in acute lymphoblastic leukemia.

Tumor-induced dendritic cell deregulation perturbs T cell proliferation and predicts clinical outcome in acute lymphoblastic leukemia.

Journal: Cell reports. Medicine

Published: November 21, 2025

A Phase I Study of Carfilzomib with Cyclophosphamide and Etoposide in Relapsed and Refractory Leukemia and Solid Tumors.

A Phase I Study of Carfilzomib with Cyclophosphamide and Etoposide in Relapsed and Refractory Leukemia and Solid Tumors.

Journal: Cancers

Published: July 31, 2025

Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1/2 study.

Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm phase 1/2 study.

Journal: The Lancet. Haematology

Published: July 03, 2025

DHODH as a Targetable Metabolic Achilles' Heel for chemo-resistant B-ALL.

DHODH as a Targetable Metabolic Achilles' Heel for chemo-resistant B-ALL.

Journal: Blood

Published: March 20, 2025

DHODH as a targetable metabolic Achilles' heel for chemotherapy-resistant B-ALL.

DHODH as a targetable metabolic Achilles' heel for chemotherapy-resistant B-ALL.

Journal: Blood

Published: March 20, 2025

Uridine Metabolism as a Targetable Metabolic Achilles' Heel for chemo-resistant B-ALL.

Uridine Metabolism as a Targetable Metabolic Achilles' Heel for chemo-resistant B-ALL.

Journal: bioRxiv : the preprint server for biology

Published: February 20, 2025

Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: February 12, 2025

Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition.

Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition.

Journal: Blood neoplasia

Published: July 29, 2024

Pharmacogenomics, Race, and Treatment Outcome in Pediatric Acute Myeloid Leukemia.

Pharmacogenomics, Race, and Treatment Outcome in Pediatric Acute Myeloid Leukemia.

Journal: JAMA network open

Published: May 16, 2024

Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy.

Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy.

Journal: Frontiers in immunology

Published: April 25, 2024

Showing 1-12 of 56

Last Updated: 09/26/2026